Company / R&D per Share
PTC Therapeutics, Inc. R&D per Share History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D per Share
$5.86
FY2025
5-year range
$3.69 / $9.12
FY2021-FY2025
Trend
-17.0%
vs FY2024
Sector context
#25 of 208
Health Care
What the data says
PTC Therapeutics, Inc.'s r&d per share of $5.86 is higher than 88% of companies in the Health Care sector (FY2025). R&D per Share has fluctuated over the past 10 years, ranging from $2.78 in FY2020 to $9.12 in FY2023.
Based on SEC 10-K filings.
5.86 in FY2025 with a 5-year CAGR of +16.1%. Top quartile in the Health Care sector.
Declined from $9.12 to $5.86 over the past 2 years.
Health Care sector context is included.
R&D per Share over time
Growth rates
- 3-Year CAGR
- -4.6%
- 5-Year CAGR
- +16.1%
- 10-Year CAGR
- -
Sector benchmark
Top 12% in Health CareTop 12% of 208This company $5.86 Sector average $12.19
▼
-52.0% below sector average
Key checks
Key Insights
- In FY2025, r&d per share decreased 17.0% year-over-year.
- Ranks #25 out of 208 companies in the Health Care sector.
- Peak r&d per share was recorded in FY2023.
- Lowest r&d per share in the period was in FY2020.
Company context
Key Data Points
- Altman Z-Score 0.95 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $5.86 | -17.0% |
| FY2024 | $7.06 | -22.6% |
| FY2023 | $9.12 | +35.2% |
| FY2022 | $6.74 | +82.6% |
| FY2021 | $3.69 | +33.0% |
| FY2020 | $2.78 | -36.5% |
| FY2019 | $4.37 | +5.8% |
| FY2018 | $4.13 | +20.2% |
| FY2017 | $3.44 | -0.9% |
| FY2016 | $3.47 | -6.3% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026